• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于缩小预测概率的两药联合Ⅰ期临床试验剂量探索方法。

A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.

机构信息

Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Aichi, 466-8560, Japan.

出版信息

Stat Med. 2013 Nov 20;32(26):4515-25. doi: 10.1002/sim.5843. Epub 2013 May 6.

DOI:10.1002/sim.5843
PMID:23650098
Abstract

We develop a novel dose-finding method for two-agent combination phase I trials on the basis of the shrunken predictive probability of toxicity. In this method, a shrinkage logistic regression model that allows distinct shrinkage multipliers for the coefficients of the main effects of two agents and their interaction on the probability of toxicity constructs the toxicity outcome. We also propose dose-escalation/de-escalation decision rules on the basis of the shrunken predictive probability of toxicity. Simulation studies under various patterns of monotonic dose-response relationships for combinations of two agents demonstrated that the proposed method performed no worse than the existing two dose-finding methods we selected.

摘要

我们基于毒性缩小预测概率开发了一种新的两药联合Ⅰ期试验剂量探索方法。在这种方法中,构建毒性结果的是一个允许两个药物的主效应及其相互作用的系数有不同收缩倍数的收缩逻辑回归模型。我们还基于毒性缩小预测概率提出了剂量递增/递减决策规则。在两个药物组合的各种单调剂量反应模式下的模拟研究表明,所提出的方法并不逊于我们选择的两种现有的剂量探索方法。

相似文献

1
A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.基于缩小预测概率的两药联合Ⅰ期临床试验剂量探索方法。
Stat Med. 2013 Nov 20;32(26):4515-25. doi: 10.1002/sim.5843. Epub 2013 May 6.
2
Escalation with overdose control for phase I drug-combination trials.I期药物联合试验中过量控制的剂量递增
Stat Med. 2013 Nov 10;32(25):4400-12. doi: 10.1002/sim.5832. Epub 2013 Apr 30.
3
Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui.对平川晃洋、滨田智磨和松井重之的《I期试验中基于两种药物组合的收缩预测概率的剂量探索方法》的评论
Stat Med. 2014 May 30;33(12):2156-8. doi: 10.1002/sim.5934.
4
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.一种在I/II期剂量探索试验中对毒性和生物标志物表达进行联合建模的贝叶斯方法。
Biometrics. 2005 Jun;61(2):343-54. doi: 10.1111/j.1541-0420.2005.00314.x.
5
A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.比较Ⅰ期癌症试验中连续评估方法的模型选择。
Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682.
6
Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.贝叶斯工作模型选择的连续再评估方法中的后验最大化和平均化。
Stat Med. 2011 Jun 15;30(13):1563-73. doi: 10.1002/sim.4054. Epub 2011 Feb 24.
7
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.用于癌症I期临床试验的灵活贝叶斯方法。具有过量控制的剂量递增。
Stat Med. 2005 Jul 30;24(14):2183-96. doi: 10.1002/sim.2106.
8
A Bayesian dose finding design for dual endpoint phase I trials.用于双终点I期试验的贝叶斯剂量探索设计。
Stat Med. 2006 Jan 15;25(1):3-22. doi: 10.1002/sim.2303.
9
An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.一种用于 I 期肿瘤临床试验中相关二元二项和连续结局的自适应剂量探索方法。
Stat Med. 2012 Mar 15;31(6):516-32. doi: 10.1002/sim.4425. Epub 2011 Nov 23.
10
Phase I trial design for drug combinations with Bayesian model averaging.采用贝叶斯模型平均法的药物联合方案的I期试验设计
Pharm Stat. 2015 Mar-Apr;14(2):108-19. doi: 10.1002/pst.1668. Epub 2015 Jan 13.

引用本文的文献

1
Seamless monotherapy-combination phase I dose-escalation model-based design.基于无缝单药治疗 - 联合治疗I期剂量递增模型的设计。
Clin Trials. 2025 Aug;22(4):430-441. doi: 10.1177/17407745251350604. Epub 2025 Jul 12.
2
Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.基于模拟研究对联合用药的I期临床试验设计进行评估并给出指导意见。
J Appl Stat. 2022 Aug 3;50(9):2055-2078. doi: 10.1080/02664763.2022.2105827. eCollection 2023.
3
Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.
I期肿瘤药物联合试验新设计的准确性和安全性
Stat Biopharm Res. 2022;14(3):270-282. doi: 10.1080/19466315.2022.2081602. Epub 2022 Aug 2.
4
How to design a dose-finding study on combined agents: Choice of design and development of R functions.如何设计联合用药的剂量探索研究:设计选择和 R 函数开发。
PLoS One. 2019 Nov 11;14(11):e0224940. doi: 10.1371/journal.pone.0224940. eCollection 2019.
5
CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.CRM2DIM:一个用于实现双代理贝叶斯连续再评估方法的 SAS 宏。
Comput Methods Programs Biomed. 2019 Jul;176:211-223. doi: 10.1016/j.cmpb.2019.04.025. Epub 2019 May 6.
6
AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.AAA:用于双药剂量探索试验中确定最佳剂量组合的三重自适应贝叶斯设计
J R Stat Soc Ser C Appl Stat. 2019 Feb;68(2):385-410. doi: 10.1111/rssc.12291. Epub 2018 Jun 13.
7
Identifying a maximum tolerated contour in two-dimensional dose finding.在二维剂量探索中确定最大耐受轮廓。
Stat Med. 2017 Jan 30;36(2):242-253. doi: 10.1002/sim.6918. Epub 2016 Feb 22.
8
Practical designs for Phase I combination studies in oncology.肿瘤学中I期联合研究的实用设计。
J Biopharm Stat. 2016;26(1):150-66. doi: 10.1080/10543406.2015.1092029.
9
A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.联合疗法肿瘤学I期试验适应性剂量探索设计的比较研究。
Stat Med. 2015 Oct 30;34(24):3194-213. doi: 10.1002/sim.6533. Epub 2015 May 13.